MarketCapExport financials
Vertex Pharmaceuticals Incorporated (VRTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Vertex Pharmaceuticals Incorporated Balance Sheet 2025-2007 | VRTX
Brief overview of Vertex Pharmaceuticals Incorporated's financial position
The comparison uses five available annual reports from the 2021–2025 interval.
Assets rose from $13.4 billion to $25.6 billion, a gain of +90.9%, while CAGR was about 17.5%. The balance sheet expanded rapidly.
Liabilities grew faster than assets: +109.4% versus +90.9%. A substantial part of expansion was externally funded.
The equity-to-assets ratio is 72.8%, compared with 75.2% five periods ago. The balance sheet has a substantial internal cushion.
The balance sheet holds more cash than interest-bearing debt; net debt is -$4.9 billion, indicating minimal leverage.
Cash accounts for 19.8% of assets versus 50.6% initially. The change indicates the degree of financial flexibility.
Accumulated earnings ended at $13.6 billion, a change of +323.6%. They remain an important part of the capital base.
Conclusion
Vertex Pharmaceuticals Incorporated's financial position is positive on balance sheet evidence. Growth in resources has not undermined capital strength.
Annual Balance Sheet Vertex Pharmaceuticals Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-4.9 B | -4.37 B | -9.96 B | -10 B | -6.25 B | -5.44 B | -2.57 B | -2.06 B | -1.06 B | -587 M | -419 M | -330 M | -62.7 M | 742 M | 418 M | - | - | - | - |
Long Term Debt |
107 M | 113 M | 376 M | 431 M | 510 M | 539 M | - | - | - | 297 M | 224 M | 281 M | - | 400 M | 400 M | - | - | - | - |
Long Term Debt Current |
77.3 M | 87.1 M | 33.1 M | 48.6 M | 33.3 M | 10.5 M | 11.5 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
3.12 B | 2.56 B | 1.6 B | 1.5 B | 1.19 B | 1.19 B | 898 M | 690 M | 696 M | 766 M | 899 M | 870 M | 565 M | 1.13 B | 846 M | 747 M | 574 M | - | - |
Total Current Liabilities |
3.86 B | 3.56 B | 3.55 B | 2.74 B | 2.14 B | 1.88 B | 1.33 B | 1.12 B | 807 M | 793 M | 506 M | 368 M | 398 M | 433 M | 392 M | 475 M | 285 M | - | - |
Total Liabilities |
6.98 B | 6.12 B | 5.15 B | 4.24 B | 3.33 B | 3.06 B | 2.23 B | 1.81 B | 1.5 B | 1.56 B | 1.41 B | 1.24 B | 963 M | 1.56 B | 1.24 B | 1.22 B | 859 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 238 M | 79.4 M | 16.3 M | 17.5 M | 21.5 M | 27.6 M | 45 M | 74.6 M | 75 M | - | - |
Retained Earnings |
13.6 B | 9.61 B | 10.1 B | 6.52 B | 3.2 B | 859 M | -1.85 B | -2.99 B | -5.12 B | -5.37 B | -5.26 B | -4.71 B | -3.97 B | -3.52 B | -3.41 B | -3.44 B | -2.69 B | - | - |
Total Assets |
25.6 B | 22.5 B | 22.7 B | 18.2 B | 13.4 B | 11.8 B | 8.32 B | 6.25 B | 3.55 B | 2.9 B | 2.5 B | 2.33 B | 2.32 B | 2.76 B | 2.2 B | 1.73 B | 1.96 B | - | - |
Cash and Cash Equivalents |
5.08 B | 4.57 B | 10.4 B | 10.5 B | 6.8 B | 5.99 B | 3.11 B | 2.65 B | 1.67 B | 1.18 B | 715 M | 625 M | 569 M | 489 M | 475 M | 243 M | 447 M | 389 M | 356 M |
Book Value |
18.7 B | 16.4 B | 17.6 B | 13.9 B | 10.1 B | 8.69 B | 6.09 B | 4.44 B | 2.04 B | 1.34 B | 1.09 B | 1.1 B | 1.36 B | 1.2 B | 966 M | 504 M | 1.1 B | - | - |
Total Shareholders Equity |
18.7 B | 16.4 B | 17.6 B | 13.9 B | 10.1 B | 8.69 B | 6.09 B | 4.44 B | 2.03 B | 1.16 B | 940 M | 1.08 B | 1.36 B | 999 M | 787 M | 504 M | 1.1 B | 239 M | 271 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Vertex Pharmaceuticals Incorporated
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.98 B | 1.98 B | 1.99 B | 1.85 B | 1.83 B | 1.53 B | 1.54 B | 1.54 B | 1.59 B | 587 M | 360 M | 349 M | 354 M | 364 M | 372 M | 380 M | 382 M | 365 M | 377 M | 377 M | 364 M | 369 M | 368 M | 350 M | 547 M | 522 M | 533 M | 84.3 M | 63 M | 60.4 M | 63.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 105 M | 105 M | 105 M | - | - | - | - |
Total Non Current Liabilities |
6.83 B | 3.24 B | 3.24 B | 3.12 B | 3.07 B | 2.72 B | 2.6 B | 2.56 B | 2.64 B | 1.81 B | 1.57 B | 1.6 B | 1.61 B | 1.53 B | 1.52 B | 1.5 B | 1.07 B | 1.09 B | 1.17 B | 1.19 B | 1.17 B | 1.19 B | 1.19 B | 1.19 B | 1.16 B | 898 M | 893 M | 898 M | 872 M | 704 M | 713 M | 690 M | 694 M | 693 M | 695 M | 696 M | 684 M | 793 M | 774 M | 766 M | 678 M | 757 M | 820 M | 899 M | 982 M | 952 M | 866 M | 870 M | 878 M | 583 M | 593 M | 565 M | 687 M | 654 M | 1.01 B | 1.09 B | 1.05 B | 982 M | 883 M | 846 M | 812 M | 835 M | 731 M | 747 M | 927 M | 535 M | 568 M |
Total Liabilities |
11.8 B | 7.18 B | 7.12 B | 6.98 B | 7.54 B | 6.86 B | 6.38 B | 6.12 B | 6.61 B | 5.36 B | 5.37 B | 5.15 B | 5.21 B | 4.88 B | 4.54 B | 4.24 B | 3.68 B | 3.65 B | 3.35 B | 3.33 B | 3.09 B | 3.03 B | 3.13 B | 3.06 B | 3.17 B | 2.7 B | 2.43 B | 2.23 B | 2.26 B | 1.96 B | 1.82 B | 1.81 B | 1.69 B | 1.62 B | 1.52 B | 1.5 B | 1.4 B | 1.42 B | 1.26 B | 1.56 B | 1.4 B | 1.38 B | 1.37 B | 1.4 B | 1.36 B | 1.33 B | 1.17 B | 1.24 B | 1.25 B | 946 M | 966 M | 963 M | 1.1 B | 1.04 B | 1.42 B | 1.52 B | 1.45 B | 1.36 B | 1.24 B | 1.24 B | 1.36 B | 1.31 B | 1.15 B | 1.22 B | 1.24 B | 827 M | 780 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.17 M | 13 M | 7.28 M | 6.06 M | 6 M | 9.25 M | 11.5 M | 14.7 M | 16.3 M | 14 M | 14.9 M | 15.9 M | 17.5 M | 21.2 M | 27.2 M | 28.8 M | 21.5 M | 31 M | 32.9 M | 35.5 M | 27.6 M | 27.3 M | 27.3 M | 30.5 M | 45 M | 55.7 M | 65 M | 74.2 M | 74.6 M | 99 M | 78.3 M | 69.6 M |
Retained Earnings |
16.3 B | 15.7 B | 14.6 B | 13.6 B | 12.4 B | 11.3 B | 10.3 B | 9.61 B | 8.69 B | 7.65 B | 11.2 B | 10.1 B | 9.17 B | 8.14 B | 7.22 B | 6.52 B | 5.7 B | 4.77 B | 3.96 B | 3.2 B | 2.43 B | 1.58 B | 1.51 B | 859 M | 254 M | -413 M | -1.25 B | -1.85 B | -2.44 B | -2.49 B | -2.76 B | -2.99 B | -4.54 B | -4.67 B | -4.88 B | -5.12 B | -5.22 B | -5.12 B | -5.14 B | -5.37 B | -5.41 B | -5.37 B | -5.3 B | -5.26 B | -5.19 B | -5.09 B | -4.9 B | -4.71 B | -4.53 B | -4.36 B | -4.2 B | -3.97 B | -4.01 B | -3.89 B | -3.83 B | -3.52 B | -3.45 B | -3.39 B | -3.32 B | -3.41 B | -3.57 B | -3.79 B | -3.62 B | -3.44 B | -3.26 B | -3.06 B | -2.86 B |
Total Assets |
32.7 B | 27.4 B | 26.5 B | 25.6 B | 24.9 B | 24 B | 22.9 B | 22.5 B | 22.2 B | 20.1 B | 23.9 B | 22.7 B | 21.7 B | 20.3 B | 19 B | 18.2 B | 16.7 B | 15.6 B | 14.3 B | 13.4 B | 12.6 B | 12.2 B | 12.1 B | 11.8 B | 11.3 B | 10.2 B | 8.89 B | 8.32 B | 7.51 B | 7.03 B | 6.54 B | 6.25 B | 4.62 B | 4.34 B | 3.95 B | 3.55 B | 3.2 B | 3.29 B | 2.95 B | 2.9 B | 2.61 B | 2.55 B | 2.49 B | 2.5 B | 2.43 B | 2.37 B | 2.17 B | 2.33 B | 2.41 B | 2.12 B | 2.2 B | 2.32 B | 2.58 B | 2.58 B | 2.39 B | 2.76 B | 2.72 B | 2.6 B | 2.35 B | 2.2 B | 2.09 B | 1.76 B | 1.54 B | 1.73 B | 1.89 B | 1.65 B | 1.77 B |
Cash and Cash Equivalents |
4.99 B | 6.15 B | 5.5 B | 5.09 B | 4.95 B | 4.98 B | 4.69 B | 4.57 B | 5.25 B | 4.59 B | 9.17 B | 10.4 B | 11.1 B | 10.2 B | 9.3 B | 10.5 B | 9.18 B | 8.7 B | 7.6 B | 6.8 B | 6.28 B | 6.07 B | 6.31 B | 5.99 B | 5.36 B | 4.84 B | 3.6 B | 3.12 B | 3.4 B | 3.3 B | 2.9 B | 2.66 B | 2.49 B | 2.15 B | 2.01 B | 1.67 B | 1.39 B | 1.29 B | 1.05 B | 1.23 B | 720 M | 606 M | 604 M | 816 M | 756 M | 871 M | 665 M | 625 M | 719 M | 421 M | 424 M | 569 M | 583 M | 531 M | 379 M | 489 M | 437 M | 454 M | 454 M | 475 M | 543 M | 458 M | 447 M | 243 M | 570 M | 338 M | 397 M |
Book Value |
20.9 B | 20.2 B | 19.4 B | 18.7 B | 17.3 B | 17.2 B | 16.5 B | 16.4 B | 15.6 B | 14.8 B | 18.5 B | 17.6 B | 16.5 B | 15.5 B | 14.4 B | 13.9 B | 13 B | 11.9 B | 10.9 B | 10.1 B | 9.53 B | 9.2 B | 8.98 B | 8.69 B | 8.13 B | 7.52 B | 6.46 B | 6.09 B | 5.25 B | 5.07 B | 4.72 B | 4.44 B | 2.93 B | 2.71 B | 2.43 B | 2.04 B | 1.8 B | 1.87 B | 1.68 B | 1.34 B | 1.21 B | 1.17 B | 1.12 B | 1.09 B | 1.08 B | 1.05 B | 998 M | 1.1 B | 1.16 B | 1.17 B | 1.23 B | 1.36 B | 1.49 B | 1.55 B | 977 M | 1.23 B | 1.26 B | 1.24 B | 1.11 B | 966 M | 731 M | 449 M | 392 M | 504 M | 650 M | 827 M | 991 M |
Total Shareholders Equity |
20.9 B | 20.2 B | 19.4 B | 18.7 B | 17.3 B | 17.2 B | 16.5 B | 16.4 B | 15.6 B | 14.8 B | 18.5 B | 17.6 B | 16.5 B | 15.5 B | 14.4 B | 13.9 B | 13 B | 11.9 B | 10.9 B | 10.1 B | 9.53 B | 9.2 B | 8.98 B | 8.69 B | 8.13 B | 7.52 B | 6.46 B | 6.09 B | 5.25 B | 5.07 B | 4.72 B | 4.44 B | 2.93 B | 2.71 B | 2.43 B | 2.04 B | 1.8 B | 1.87 B | 1.68 B | 1.34 B | 1.21 B | 1.17 B | 1.12 B | 1.09 B | 1.08 B | 1.05 B | 998 M | 1.1 B | 1.16 B | 1.17 B | 1.23 B | 1.36 B | 1.45 B | 1.51 B | 938 M | 1.2 B | 1.23 B | 1.21 B | 1.07 B | 928 M | 694 M | 413 M | 392 M | 504 M | 650 M | 827 M | 991 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Vertex Pharmaceuticals Incorporated, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
